Author Correction: Disrupting TSLP-TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases

Partho Protim Adhikary¹, Temilolu Idowu¹, Zheng Tan¹, Christopher Hoang¹, Selina Shanta¹, Malti Dumbani², Leah Mappalakayil¹, Bhuwan Awasthi¹, Marcel Bermudez^{2

3}, January Weiner⁴, Dieter Beule⁴, Gerhard Wolber², Brent D G Page⁵, Sarah Hedtrich^{6

7

8

9}

Affiliations

¹ Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.
² Institute of Pharmacy, Freie Universität of Berlin, Berlin, Germany.
³ Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität Münster, Münster, Germany.
⁴ Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁵ Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada. brent.page@ubc.ca.
⁶ Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada. sarah.hedtrich@bih-charite.de.
⁷ Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany Charité - Universitätsmedizin Berlin, Berlin, Germany. sarah.hedtrich@bih-charite.de.
⁸ Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany. sarah.hedtrich@bih-charite.de.
⁹ Max-Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125, Berlin, Germany. sarah.hedtrich@bih-charite.de.

Published Erratum

Partho Protim Adhikary et al. EMBO Mol Med. 2024 Dec.

. 2024 Dec;16(12):3247-3250.

doi: 10.1038/s44321-024-00165-4.

¹ Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.
² Institute of Pharmacy, Freie Universität of Berlin, Berlin, Germany.
³ Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität Münster, Münster, Germany.
⁴ Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁵ Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada. brent.page@ubc.ca.
⁶ Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada. sarah.hedtrich@bih-charite.de.
⁷ Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany Charité - Universitätsmedizin Berlin, Berlin, Germany. sarah.hedtrich@bih-charite.de.
⁸ Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany. sarah.hedtrich@bih-charite.de.
⁹ Max-Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125, Berlin, Germany. sarah.hedtrich@bih-charite.de.

Abstract

Disrupting TSLP-TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases.
Adhikary PP, Idowu T, Tan Z, Hoang C, Shanta S, Dumbani M, Mappalakayil L, Awasthi B, Bermudez M, Weiner J, Beule D, Wolber G, Page BD, Hedtrich S. Adhikary PP, et al. EMBO Mol Med. 2024 Jul;16(7):1630-1656. doi: 10.1038/s44321-024-00085-3. Epub 2024 Jun 14. EMBO Mol Med. 2024. PMID: 38877290 Free PMC article.